158 related articles for article (PubMed ID: 25910560)
1. Genetic polymorphisms of CYP2C19 and IL1B have no influence on esomeprazole treatment for mild erosive esophagitis.
Hsu WH; Kuo FC; Hu HM; Hsu PI; Wu DC; Kuo CH
Kaohsiung J Med Sci; 2015 May; 31(5):255-9. PubMed ID: 25910560
[TBL] [Abstract][Full Text] [Related]
2. Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis.
Zendehdel N; Biramijamal F; Hossein-Nezhad A; Zendehdel N; Sarie H; Doughaiemoghaddam M; Pourshams A
Arch Iran Med; 2010 Sep; 13(5):406-12. PubMed ID: 20804307
[TBL] [Abstract][Full Text] [Related]
3. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis.
Ichikawa H; Sugimoto M; Sugimoto K; Andoh A; Furuta T
J Gastroenterol Hepatol; 2016 Apr; 31(4):716-26. PubMed ID: 26580676
[TBL] [Abstract][Full Text] [Related]
4. Factors associated with residual gastroesophageal reflux disease symptoms in patients receiving proton pump inhibitor maintenance therapy.
Kawara F; Fujita T; Morita Y; Uda A; Masuda A; Saito M; Ooi M; Ishida T; Kondo Y; Yoshida S; Okuno T; Yano Y; Yoshida M; Kutsumi H; Hayakumo T; Yamashita K; Hirano T; Hirai M; Azuma T
World J Gastroenterol; 2017 Mar; 23(11):2060-2067. PubMed ID: 28373773
[TBL] [Abstract][Full Text] [Related]
5. Esomeprazole for the Treatment of Erosive Esophagitis in Children: An International, Multicenter, Randomized, Parallel-Group, Double-Blind (for Dose) Study.
Tolia V; Youssef NN; Gilger MA; Traxler B; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S24-30. PubMed ID: 26121347
[TBL] [Abstract][Full Text] [Related]
6. Esomeprazole for the Treatment of Erosive Esophagitis in Children: An International, Multicenter, Randomized, Parallel-Group, Double-Blind (for Dose) Study.
Tolia V; Youssef NN; Gilger MA; Traxler B; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S24-30. PubMed ID: 26422095
[TBL] [Abstract][Full Text] [Related]
7. Influence of cytochrome P450 2C19 genetic polymorphism and dosage of rabeprazole on accuracy of proton-pump inhibitor testing in Chinese patients with gastroesophageal reflux disease.
Lee YC; Lin JT; Wang HP; Chiu HM; Wu MS
J Gastroenterol Hepatol; 2007 Aug; 22(8):1286-92. PubMed ID: 17559380
[TBL] [Abstract][Full Text] [Related]
8. Healing of Erosive Esophagitis and Improvement of Symptoms of Gastroesophageal Reflux Disease After Esomeprazole Treatment in Children 12 to 36 Months Old.
Tolia V; Gilger MA; Barker PN; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S31-6. PubMed ID: 26422096
[TBL] [Abstract][Full Text] [Related]
9. Healing of Erosive Esophagitis and Improvement of Symptoms of Gastroesophageal Reflux Disease After Esomeprazole Treatment in Children 12 to 36 Months Old.
Tolia V; Gilger MA; Barker PN; Illueca M
J Pediatr Gastroenterol Nutr; 2015 Jul; 60 Suppl 1():S31-6. PubMed ID: 26121348
[TBL] [Abstract][Full Text] [Related]
10. Eight weeks of esomeprazole therapy reduces symptom relapse, compared with 4 weeks, in patients with Los Angeles grade A or B erosive esophagitis.
Hsu PI; Lu CL; Wu DC; Kuo CH; Kao SS; Chang CC; Tai WC; Lai KH; Chen WC; Wang HM; Cheng JS; Tsai TJ; Chuah SK
Clin Gastroenterol Hepatol; 2015 May; 13(5):859-66.e1. PubMed ID: 25245625
[TBL] [Abstract][Full Text] [Related]
11. Esomeprazole for the treatment of erosive esophagitis in children: an international, multicenter, randomized, parallel-group, double-blind (for dose) study.
Tolia V; Youssef NN; Gilger MA; Traxler B; Illueca M
BMC Pediatr; 2010 Jun; 10():41. PubMed ID: 20540767
[TBL] [Abstract][Full Text] [Related]
12. A multicentre randomised trial to compare the efficacy of omeprazole versus rabeprazole in early symptom relief in patients with reflux esophagitis.
Nagahara A; Suzuki T; Nagata N; Sugai N; Takeuchi Y; Sakurai K; Miyamoto M; Inoue K; Akiyama J; Mabe K; Konuma I; Kamada T; Haruma K
J Gastroenterol; 2014 Dec; 49(12):1536-47. PubMed ID: 24366288
[TBL] [Abstract][Full Text] [Related]
13. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease.
Wu JC; Lai LH; Chow DK; Wong GL; Sung JJ; Chan FK
Neurogastroenterol Motil; 2011 Feb; 23(2):155-60, e31. PubMed ID: 21087355
[TBL] [Abstract][Full Text] [Related]
14. Influences of CYP2C19 polymorphism on recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy.
Saitoh T; Otsuka H; Kawasaki T; Endo H; Iga D; Tomimatsu M; Fukushima Y; Katsube T; Ogawa K; Otsuka K
Hepatogastroenterology; 2009; 56(91-92):703-6. PubMed ID: 19621685
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenomics fail to explain proton pump inhibitor refractory esophagitis in pediatric esophageal atresia.
Yasuda JL; Staffa SJ; Nurko S; Kane M; Wall S; Mougey EB; Franciosi JP; Manfredi MA; Rosen R
Neurogastroenterol Motil; 2022 Jan; 34(1):e14217. PubMed ID: 34337835
[TBL] [Abstract][Full Text] [Related]
16. Cost-Utility Analysis of CYP2C19 Genotype Detection for Selection of Acid-Suppressive Therapy with Lansoprazole or Vonoprazan for Patients with Reflux Esophagitis in China.
Zhang Z; Bao Y; Cai L; Gu Y; Yang T; Li X
Clin Drug Investig; 2022 Oct; 42(10):839-851. PubMed ID: 35994227
[TBL] [Abstract][Full Text] [Related]
17. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A
Digestion; 2017; 96(1):52-59. PubMed ID: 28662503
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-1beta genetic polymorphism influences the effect of cytochrome P 2C19 genotype on the cure rate of 1-week triple therapy for Helicobacter pylori infection.
Take S; Mizuno M; Ishiki K; Nagahara Y; Yoshida T; Inaba T; Yamamoto K; Okada H; Yokota K; Oguma K; Shiratori Y
Am J Gastroenterol; 2003 Nov; 98(11):2403-8. PubMed ID: 14638340
[TBL] [Abstract][Full Text] [Related]
19. A Randomized, Double-blind, Active-Controlled, Multi-center Study of Ilaprazole in the Treatment of Reflux Esophagitis.
Xue Y; Qin X; Zhou L; Lin S; Wang L; Hu H; Xia J
Clin Drug Investig; 2016 Dec; 36(12):985-992. PubMed ID: 27605258
[TBL] [Abstract][Full Text] [Related]
20. A review of the clinical and economic impact of using esomeprazole or lansoprazole for the treatment of erosive esophagitis.
Raghunath AS; Green JR; Edwards SJ
Clin Ther; 2003 Jul; 25(7):2088-101. PubMed ID: 12946553
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
